Setback for Huntington's disease therapy

Nature ◽  
2009 ◽  
Author(s):  
Lizzie Buchen
2006 ◽  
Vol 13 ◽  
pp. S274-S275
Author(s):  
Alex Mas-Monteys ◽  
Scott Q. Harper ◽  
Brian L. Gilmore ◽  
Patrick D. Staber ◽  
Chris Schaffer ◽  
...  

2020 ◽  
Author(s):  
Irina Kerkis ◽  
Joyce Macedo da Silva ◽  
Cristiane Valverde Wenceslau ◽  
Nicole Caroline Mambelli-Lisboa ◽  
Eduardo Osorio Frare

1988 ◽  
Vol 6 (3) ◽  
pp. 290-303 ◽  
Author(s):  
M. Michele Murburg ◽  
Lawrence H. Price ◽  
Behnaz Jalali

2010 ◽  
Vol 10 ◽  
pp. 1768-1782 ◽  
Author(s):  
Maria Teresa Tebano ◽  
Alberto Martire ◽  
Valentina Chiodi ◽  
Antonella Ferrante ◽  
Patrizia Popoli

In the last few years, accumulating evidence has shown the existence of an important cross-talk between adenosine A2Areceptors (A2ARs) and brain-derived neurotrophic factor (BDNF). Not only are A2ARs involved in the mechanism of transactivation of BDNF receptor TrkB, they also modulate the effect of BDNF on synaptic transmission, playing a facilitatory and permissive role. The cAMP-PKA pathway, the main transduction system operated by A2ARs, is involved in such effects. Furthermore, a basal tonus of A2ARs is required to allow the regulation of BDNF physiological levels in the brain, as demonstrated by the reduced protein levels measured in A2ARs KO mice. The crucial role of adenosine A2ARs in the maintenance of synaptic functions and BDNF levels will be reviewed here and discussed in the light of possible implications for Huntington's disease therapy, in which a joint impairment of BDNF and A2ARs seems to play a pathogenetic role.


2007 ◽  
Vol 28 (3) ◽  
pp. 445-449 ◽  
Author(s):  
Evandro Ferrada ◽  
Verónica Arancibia ◽  
Bárbara Loeb ◽  
Ester Norambuena ◽  
Claudio Olea-Azar ◽  
...  

2012 ◽  
Vol 83 (Suppl 1) ◽  
pp. A54.1-A54
Author(s):  
C Reick ◽  
C Saft ◽  
RA Linker ◽  
S Wiese ◽  
R Gold ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document